T-cell activity is often suppressed by the immunosuppressive nature of the tumor microenvironment, contributing to the ...

CDR-Life Inc. has announced CDR-609 as its next clinical candidate. Built on the company’s proprietary M-gager platform, ...

Abion Inc. signed a potential $1.315 billion deal with an anonymous partner June 22, granting the counterparty exclusive ...

The rapid adoption of the Omnipod 5 answered a question automated insulin delivery system manufacturers posed for years: with ...

B4, to its pipeline for prevention of group A Streptococcus (GAS) infections. Invasive GAS infections can cause diseases such ...

Edgewise Therapeutics Inc. CEO Kevin Koch speculated that “perhaps a different environment at the FDA” from four months ago ...

Aprea Therapeutics Inc. has announced new preclinical data on APR-1051, the company’s next-generation oral WEE1 inhibitor, in ...

Novo Nordisk A/S recently presented data regarding their antibody fragment Inno-8 for the potential treatment of hemophilia A ...

Visceral leishmaniasis is a fatal disease caused by the Leishmania parasite, affecting organs such as the liver and spleen. Visceral leishmaniasis is considered a neglected tropical disease and is ...

Abvance Therapeutics Inc. secured an undisclosed amount of capital in a seed round led by Zubi Capital to support development ...

BioWorld tracked 223 clinical trial updates across phases I to III in May 2025, marking an increase from 197 in March and 151 in April. Among these, 17 trials reported positive phase III results, ...

Muscarinic M4 receptor positive allosteric modulators are detailed in an Acadia Pharmaceuticals Inc. patent. They are reported to be useful for the treatment of Alzheimer’s disease, pain, ...